Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010064672> ?p ?o ?g. }
- W3010064672 endingPage "577" @default.
- W3010064672 startingPage "577" @default.
- W3010064672 abstract "The survivin suppressant YM155 is a drug candidate for neuroblastoma. Here, we tested YM155 in 101 neuroblastoma cell lines (19 parental cell lines, 82 drug-adapted sublines). Seventy seven (77) cell lines displayed YM155 IC50s in the range of clinical YM155 concentrations. ABCB1 was an important determinant of YM155 resistance. The activity of the ABCB1 inhibitor zosuquidar ranged from being similar to that of the structurally different ABCB1 inhibitor verapamil to being 65-fold higher. ABCB1 sequence variations may be responsible for this, suggesting that the design of variant-specific ABCB1 inhibitors may be possible. Further, we showed that ABCC1 confers YM155 resistance. Previously, p53 depletion had resulted in decreased YM155 sensitivity. However, TP53-mutant cells were not generally less sensitive to YM155 than TP53 wild-type cells in this study. Finally, YM155 cross-resistance profiles differed between cells adapted to drugs as similar as cisplatin and carboplatin. In conclusion, the large cell line panel was necessary to reveal an unanticipated complexity of the YM155 response in neuroblastoma cell lines with acquired drug resistance. Novel findings include that ABCC1 mediates YM155 resistance and that YM155 cross-resistance profiles differ between cell lines adapted to drugs as similar as cisplatin and carboplatin." @default.
- W3010064672 created "2020-03-13" @default.
- W3010064672 creator A5018385122 @default.
- W3010064672 creator A5020801776 @default.
- W3010064672 creator A5034844089 @default.
- W3010064672 creator A5041458789 @default.
- W3010064672 creator A5048920237 @default.
- W3010064672 creator A5052657395 @default.
- W3010064672 creator A5054810742 @default.
- W3010064672 creator A5058177040 @default.
- W3010064672 creator A5067741256 @default.
- W3010064672 creator A5071089769 @default.
- W3010064672 creator A5074740364 @default.
- W3010064672 date "2020-03-02" @default.
- W3010064672 modified "2023-09-26" @default.
- W3010064672 title "Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines" @default.
- W3010064672 cites W1500940860 @default.
- W3010064672 cites W1524546298 @default.
- W3010064672 cites W1821613298 @default.
- W3010064672 cites W1962829011 @default.
- W3010064672 cites W1966733922 @default.
- W3010064672 cites W1969391810 @default.
- W3010064672 cites W1979352058 @default.
- W3010064672 cites W1984529434 @default.
- W3010064672 cites W1987283660 @default.
- W3010064672 cites W1997019712 @default.
- W3010064672 cites W1998971866 @default.
- W3010064672 cites W2004954333 @default.
- W3010064672 cites W2005867761 @default.
- W3010064672 cites W2006798419 @default.
- W3010064672 cites W2012687605 @default.
- W3010064672 cites W2016431114 @default.
- W3010064672 cites W2019619416 @default.
- W3010064672 cites W2019926646 @default.
- W3010064672 cites W2020579083 @default.
- W3010064672 cites W2028598028 @default.
- W3010064672 cites W2032211985 @default.
- W3010064672 cites W2035129407 @default.
- W3010064672 cites W2037249620 @default.
- W3010064672 cites W2039517106 @default.
- W3010064672 cites W2040004169 @default.
- W3010064672 cites W2043058822 @default.
- W3010064672 cites W2048536578 @default.
- W3010064672 cites W2057000572 @default.
- W3010064672 cites W2064013031 @default.
- W3010064672 cites W2068577449 @default.
- W3010064672 cites W2082349862 @default.
- W3010064672 cites W2087681835 @default.
- W3010064672 cites W2105253056 @default.
- W3010064672 cites W2113681251 @default.
- W3010064672 cites W2119010359 @default.
- W3010064672 cites W2121846636 @default.
- W3010064672 cites W2130177169 @default.
- W3010064672 cites W2130189600 @default.
- W3010064672 cites W2139533680 @default.
- W3010064672 cites W2140446403 @default.
- W3010064672 cites W2140712673 @default.
- W3010064672 cites W2148583743 @default.
- W3010064672 cites W2151052146 @default.
- W3010064672 cites W2152141362 @default.
- W3010064672 cites W2154563079 @default.
- W3010064672 cites W2157897307 @default.
- W3010064672 cites W2165656117 @default.
- W3010064672 cites W2172124462 @default.
- W3010064672 cites W2182640977 @default.
- W3010064672 cites W2229843531 @default.
- W3010064672 cites W2283420536 @default.
- W3010064672 cites W2295110062 @default.
- W3010064672 cites W2418045530 @default.
- W3010064672 cites W2515257886 @default.
- W3010064672 cites W2518301625 @default.
- W3010064672 cites W2530170227 @default.
- W3010064672 cites W2560917069 @default.
- W3010064672 cites W2925395230 @default.
- W3010064672 cites W2969272216 @default.
- W3010064672 cites W47603266 @default.
- W3010064672 doi "https://doi.org/10.3390/cancers12030577" @default.
- W3010064672 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7139505" @default.
- W3010064672 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32131402" @default.
- W3010064672 hasPublicationYear "2020" @default.
- W3010064672 type Work @default.
- W3010064672 sameAs 3010064672 @default.
- W3010064672 citedByCount "6" @default.
- W3010064672 countsByYear W30100646722021 @default.
- W3010064672 countsByYear W30100646722022 @default.
- W3010064672 crossrefType "journal-article" @default.
- W3010064672 hasAuthorship W3010064672A5018385122 @default.
- W3010064672 hasAuthorship W3010064672A5020801776 @default.
- W3010064672 hasAuthorship W3010064672A5034844089 @default.
- W3010064672 hasAuthorship W3010064672A5041458789 @default.
- W3010064672 hasAuthorship W3010064672A5048920237 @default.
- W3010064672 hasAuthorship W3010064672A5052657395 @default.
- W3010064672 hasAuthorship W3010064672A5054810742 @default.
- W3010064672 hasAuthorship W3010064672A5058177040 @default.
- W3010064672 hasAuthorship W3010064672A5067741256 @default.
- W3010064672 hasAuthorship W3010064672A5071089769 @default.
- W3010064672 hasAuthorship W3010064672A5074740364 @default.
- W3010064672 hasBestOaLocation W30100646721 @default.